NCT06224270 - Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications | Biotech Hunter

Timeline

Start Date

October 31, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Inflammatory Bowel DiseasesIBD

Interventions

BIOLOGICAL

Adjuvanted Recombinant Zoster Vaccine (RZV)

The RZV vaccine is indicated for prevention of herpes zoster (HZ) in adults aged 18 years and older who are or will be at increased risk of HZ. Patients with IBD on immunosuppressive therapy are at increased risk for HZ.

Trial Locations (6)

10012

New York University, New York

21202

Mercy Medical Center, Baltimore

27599

University of North Carolina, Chapel Hill

32224

Mayo Clinic, Jacksonville

37235

Vanderbilt University, Nashville

53792

UW Hospital and Clinics, Madison